Skip to content

Effect of enteral immunonutrition on the nutritional status and intestinal mucosal barrier function of postoperative chemotherapy patients with gastric cancer

Effect of enteral immunonutrition on the nutritional status and intestinal mucosal barrier function of postoperative chemotherapy patients with gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105949
Enrollment
Unknown
Registered
2025-07-15
Start date
2025-07-21
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Experimental group:Individualized nutritional intervention program was given including nutritional education and oral enteral immunonutrition preparation. The enteral immunonutrition preparation was p
Control subjects:Give regular dietary instructions and natural meals.

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) Aged 18 to 85 years old; 2) Having undergone radical surgery for gastric cancer with pathologic results confirming the diagnosis of gastric cancer; 3) Those who are proposed to undergo postoperative sox adjuvant chemotherapy regimen for gastric malignant tumors for the first time; 4) Voluntarily participate in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1) Those who have undergone neoadjuvant chemotherapy prior to surgery; 2) Those who are intolerant to enteral immunonutrition preparations used in this trial; 3) those who are combined with other malignant tumors; (4) Those with severe cardiovascular, cerebral, hepatic and renal function abnormalities; 5) patients during pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
Anthropometric Nutritional Indicators;Serum nutritional indicators;NR2002 score;PG-SGA score;Intestinal mucosal barrier function;Chemotherapy-related adverse effects and tolerability;Physical mobility;

Secondary

MeasureTime frame
QLQ-C30 score;Six minutes walking distance;

Countries

China

Contacts

Public ContactPan Yujuan

The First Affiliated Hospital of Nanchang University

41417377@qq.com+86 150 0700 1680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026